Skip to main content

Genzyme to Sell Third Wave s Colorectal Cancer PGx Test in North America

NEW YORK, Oct. 27 (GenomeWeb News) - Genzyme Genetics will sell Third Wave's Invader UGT1A1 molecular assay to identify colorectal cancer patients who could be considered for, or currently undergoing, chemotherapy with Camptosar, the companies said today.

Besides launching the test in North America, Genzyme will begin a "direct education program" aimed at oncologists and pathologists in that market the companies said.

The Invader UGT1A1 molecular assay identifies patients who may be at increased risk for adverse reactions to Camptosar, developed by Pharmacia, by detecting variations in the UGT1A1 gene that have been associated with that risk.

 

A clinical study indicated that patients with one of these variations have a greater than nine-fold increased risk of experiencing toxicity from Camptosar than patients without the variation, the companies said. As such, Camptosar's labeling was recently updated to include dosing recommendations based on a patient's UGT1A1 status.

Wave said it will make the assay available to its current customers.

 

Financial details were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.